

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated September 13, 2023 (the “**Prospectus**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an invitation to induce an offer or an offer to sell, acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold solely outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 2496)

**PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION
STABILIZING ACTIONS
AND END OF STABILIZATION PERIOD**

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Overall Coordinator for itself and on behalf of the International Underwriters on Wednesday, October 18, 2023 in respect of an aggregate of 848,000 H Shares, representing approximately 7.71% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the International Offering, at HK\$16.00 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%).

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Wednesday, October 18, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by China Securities (International) Corporate Finance Company Limited, the Stabilizing Manager, or its affiliates or any person acting for it, during the stabilization period are set out in this announcement.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Overall Coordinator for itself and on behalf of the International Underwriters on Wednesday, October 18, 2023 in respect of an aggregate of 848,000 H Shares, representing approximately 7.71% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the International Offering.

The over-allotment Shares will be allotted and issued by the Company at HK\$16.00 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per H Share under the Global Offering.

APPROVAL FOR LISTING

Approval for the listing of and permission to deal in the over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the over – allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on Tuesday, October 24, 2023 (Hong Kong time).

SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after completion of the partial exercise of the Over-allotment Option is as follows:

Description of Shares	Immediately before completion of the partial exercise of the Over-allotment Option		Immediately after completion of the partial exercise of the Over-allotment Option	
	Number of issued Shares	Approximate % of the Company's issued share capital ⁽¹⁾	Number of issued Shares	Approximate % of the Company's issued share capital ⁽¹⁾
Unlisted Shares in issue ⁽²⁾	82,380,386	42.68%	82,380,386	42.50%
H Shares converted from Unlisted Shares ⁽³⁾	99,619,614	51.62%	99,619,614	51.39%

Description of Shares	Immediately before completion of the partial exercise of the Over-allotment Option		Immediately after completion of the partial exercise of the Over-allotment Option	
	Number of issued Shares	Approximate % of the Company's issued share capital ⁽¹⁾	Number of issued Shares	Approximate % of the Company's issued share capital ⁽¹⁾
H Shares issued under the Global Offering	11,001,200	5.70%	11,849,200	6.11%
Total	193,001,200	100.00%	193,849,200	100.00%

Notes:

- (1) Any discrepancies in the table between the totals and sums of amounts listed therein are due to rounding.
- (2) The Unlisted Shares in issue refer to 20,399,933 Unlisted Shares held by Yuan Qian, 16,792,707 Unlisted Shares held by Wuhan Caizhi, 5,810,206 Unlisted Shares held by Caizhi No.2, 10,199,921 Unlisted Shares held by Dr. Zhou Hongfeng, 3,447,526 Unlisted Shares held by Huiyou Xingyao, 7,000,000 Unlisted Shares held by Guanggu New Technology, 6,869,744 Unlisted Shares held by Dr. Zhou Pengfei, 5,600,000 Unlisted Shares held by Guanggu Health, 1,611,513 Unlisted Shares held by Gongqingcheng Huiyou, 1,919,166 Unlisted Shares held by BGI Co-win Fund I, 1,400,000 Unlisted Shares held by Guanggu Growth, 959,583 Unlisted Shares held by Zhuhai Shengyi, 370,087 Unlisted Shares held by Dr. Guo Hongwei.
- (3) Following the completion of the Global Offering and according to the approval issued by the CSRC on March 30, 2023, 99,619,614 Unlisted Shares were converted into H Shares on a one-for-one basis and listed on the Stock Exchange for trading.

USE OF PROCEEDS

The Company will receive additional net proceeds of approximately HK\$12.92 million (after deducting the underwriting commissions and other estimated expenses payable by the Company in connection with the partial exercise of the Over-allotment Option) for the 848,000 H Shares to be issued and allotted following the partial exercise of the Over-allotment Option. The additional net proceeds will be used by the Company on a pro rata basis, for the purposes as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on Wednesday, October 18, 2023, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. The stabilizing actions undertaken by China Securities (International) Corporate Finance Company Limited, the Stabilizing Manager, or its affiliates or any person acting for it, during the stabilization period are set out below:

- (i) the over-allocation of an aggregate of 848,000 H Shares under the International Offering, representing approximately 7.71% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (ii) successive purchases of an aggregate of 802,000 H Shares in the price range of HK\$14.60 to HK\$16.00 per H share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%) on the market during the stabilization period, representing approximately 7.29% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last purchase made by the Stabilizing Manager or its affiliates or any person acting for it, on the market during the course of the stabilization period was on October 18, 2023 at the price of HK\$14.88 per Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%);
- (iii) the partial exercise of the Over-allotment Option by the Overall Coordinator (for itself and on behalf of the International Underwriters) on Wednesday, October 18, 2023 in respect of an aggregate of 848,000 Shares, representing approximately 7.71% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at HK\$16.00 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%), being the Offer Price per Offer Share under the Global Offering, which were used to cover the over-allocation under the International Offering.

The portion of the Over-allotment Option which has not been exercised by the Overall Coordinator for itself and on behalf of the International Underwriters lapsed on Wednesday, October 18, 2023.

PUBLIC FLOAT

Immediately after the end of the stabilization period and the completion of the partial exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman and Executive Director

Hong Kong, October 19, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Zhou Pengfei as executive director; Mr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Dr. Liu Dan, Dr. Guo Hongwei and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Dr. Dai Weiguo, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.